```html

Zollinger‑Ellison Endocrine Tumor (Gastrinoma) – A Patient‑Friendly Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition caused by a gastrin‑producing neuroendocrine tumor, commonly called a gastrinoma. These tumors arise most often in the pancreas or the duodenum (the first part of the small intestine) and secrete excess gastrin, a hormone that stimulates the stomach to make large amounts of acid. The resulting hyperacidity leads to severe peptic ulcer disease, diarrhea, and malabsorption.

Who it affects: ZES can occur at any age but most patients are diagnosed between 30 and 60 years old. Both men and women are affected equally. Approximately 25 % of gastrinomas are part of a genetic condition called multiple endocrine neoplasia type 1 (MEN 1), which also involves tumors of the parathyroid glands and pituitary gland.

Prevalence: Gastrinomas are uncommon, accounting for < 0.1 % of all gastrointestinal tumors. The overall incidence of ZES is estimated at 0.5–2 cases per million people per year (Mayo Clinic).

Symptoms

Because excess gastric acid affects many parts of the digestive system, the symptom profile can be broad. The following list includes the most common manifestations, along with brief explanations:

• Recurrent or refractory peptic ulcers – Ulcers may develop in atypical locations (e.g., jejunum) and heal slowly despite standard treatment.
• Abdominal pain – Usually a burning or gnawing pain that may improve after meals (due to acid neutralization) or worsen with fasting.
• Chronic diarrhea – Acid inactivates pancreatic enzymes and damages the intestinal mucosa, leading to malabsorption.
• Steatorrhea (fatty stools) – Result of fat malabsorption; stools may be bulky and foul‑smelling.
• Weight loss – Often secondary to malabsorption, reduced appetite, or chronic illness.
• Nausea/vomiting – Can be precipitated by the high acid load.
• Gastroesophageal reflux disease (GERD) – Acid reflux may cause heartburn and throat irritation.
• Vitamin B12 deficiency – Acid is required for the release of B12 from food; chronic deficiency can cause anemia and neuropathy.
• Gastroparesis – Delayed gastric emptying can occur in advanced disease.
• Signs of MEN 1 – Hypercalcemia from parathyroid tumors, headaches or vision changes from pituitary adenomas (these are clues to an underlying genetic syndrome).

Causes and Risk Factors

Underlying cause

Gastrinomas arise from the neuroendocrine (aka enterochromaffin) cells of the gastrointestinal tract. The exact trigger for sporadic (non‑genetic) tumors is unknown, but several mechanisms have been identified:

• Genetic mutations in the MEN1 tumor suppressor gene (found in both MEN 1‑related and some sporadic cases).
• Somatic alterations in DDX5, ATRX, and other genes involved in cell growth regulation.

Risk factors

• Multiple endocrine neoplasia type 1 (MEN 1) – Inherited autosomal‑dominant disorder; 20‑30 % of ZES patients have MEN 1.
• Family history of gastrinoma or other neuroendocrine tumors.
• Age – Risk rises after the third decade of life.
• Chronic atrophic gastritis – Long‑standing inflammation may predispose to hypergastrinemia, though it rarely leads to gastrinoma.

Diagnosis

Diagnosing ZES requires a combination of clinical suspicion, laboratory testing, and imaging. Because the disease is rare, a systematic approach helps avoid missed or delayed diagnosis.

Biochemical tests

• Fasting serum gastrin level – A value > 1000 pg/mL (or > 10 × upper limit) in the presence of low gastric pH is highly diagnostic. Levels between 100–1000 pg/mL are considered indeterminate and require further testing.
• Secretin stimulation test – Intravenous secretin normally suppresses gastrin. In ZES, gastrin paradoxically rises (≥ 120 pg/mL increase). This test has a sensitivity of ≈ 95 % (CDC).
• Gastric pH measurement – A pH < 2 confirms hyperacidity.
• 24‑hour urine gastrin – Useful when serum levels are borderline.

Imaging studies

• Multiphasic contrast‑enhanced CT scan of the abdomen – First‑line for tumor localization.
• Magnetic resonance imaging (MRI) with gadolinium – Helpful for detecting liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT – Highly sensitive for neuroendocrine tumors, especially small or metastatic lesions.
• Endoscopic ultrasound (EUS) – Allows fine‑needle aspiration of pancreatic lesions for histology.
• Selective arterial secretin injection (SASI) test – Rarely used; measures gastrin gradients from different arterial territories to pinpoint tumor location.

Pathology

If a tissue sample is obtained, pathology will show neuroendocrine cells that stain positive for chromogranin A, synaptophysin, and gastrin. The Ki‑67 proliferation index helps grade the tumor (Grade 1 = low, Grade 2 = intermediate, Grade 3 = high), which influences treatment planning.

Treatment Options

Treatment aims to control acid hypersecretion, remove or shrink the tumor, and prevent recurrence. Approach varies based on tumor size, location, presence of metastasis, and patient health.

Medical management – controlling gastric acid

• Proton pump inhibitors (PPIs) – High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses may be 2–8 times the standard ulcer dose; most patients achieve symptom control within days.
• H2‑receptor antagonists – Cimetidine or ranitidine may be added, but PPIs are superior.
• Antacids – Provide immediate relief for breakthrough symptoms.

Long‑term PPI therapy is generally safe but requires monitoring for magnesium, calcium, vitamin B12, and iron deficiencies (Cleveland Clinic).

Surgical options

• Localized curative resection – Enucleation or pancreaticoduodenectomy for tumors < 2 cm without metastasis. Success rates exceed 80 % when the tumor is confined.
• Debulking surgery – Removal of > 90 % of tumor burden in metastatic disease can improve symptom control.
• Liver metastasectomy – Considered when metastases are limited and resectable.

Targeted systemic therapies

• Somatostatin analogues (octreotide, lanreotide) – Bind somatostatin receptors, decreasing gastrin release and may shrink tumors.
• Everolimus – An mTOR inhibitor approved for progressive, well‑differentiated neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor–positive cells; shows disease control in 70‑80 % of patients.

Chemo‑embolization and radio‑embolization

For hepatic metastases not amenable to surgery, trans‑arterial chemo‑embolization (TACE) or Y‑90 radio‑embolization can reduce tumor load and acid production.

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and alcohol – these aggravate ulcer disease.
• Eat small, frequent meals; avoid large, fatty meals that stimulate acid.
• Maintain adequate hydration and replace electrolytes if diarrhea is severe.
• Supplement calcium, vitamin D, magnesium, and B12 as needed.

Living with Zollinger‑Ellison Endocrine Tumor (Gastrinoma)

Daily management tips

• Medication adherence – Take PPIs exactly as prescribed; missing doses can precipitate ulcer bleeding.
• Regular monitoring – Serum gastrin and gastric pH should be checked every 6–12 months; imaging annually if disease is stable.
• Nutrition – Work with a dietitian experienced in malabsorption. Focus on high‑protein, low‑fat foods, and consider medium‑chain triglyceride (MCT) oils to improve fat absorption.
• Bone health – Chronic PPI use and malabsorption can lower bone density. Get a DEXA scan every 2–3 years and ensure adequate calcium (1,200 mg) and vitamin D (800–1,000 IU).
• Stress management – Stress can increase gastric acid; incorporate relaxation techniques such as deep breathing, yoga, or mindfulness.

Follow‑up schedule

Visit Type	Frequency	Focus
GI specialist	Every 3–6 months	Symptom review, PPI dosing, labs (gastrin, electrolytes)
Endocrinology (if MEN 1)	Every 6–12 months	Calcium, PTH, pituitary hormone panels
Imaging (CT/MRI or DOTATATE PET)	Yearly if stable; every 3–4 months after new treatment	Detect recurrence or metastasis
Nutritionist	At diagnosis and as needed	Dietary adjustments, supplement plan

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, the following measures can reduce risk or catch disease early:

• Genetic counseling for families with MEN 1. Testing for MEN1 mutations allows surveillance from adolescence.
• Screening in high‑risk groups – Annual fasting gastrin and gastric pH in known MEN 1 carriers.
• Helicobacter pylori eradication – While not directly linked to gastrinoma, treating H. pylori reduces baseline ulcer burden and may lessen diagnostic confusion.
• Avoid chronic use of acid‑stimulating drugs (e.g., prolonged anticholinergics) that could mask early symptoms.

Complications

If left untreated or inadequately controlled, ZES can lead to serious, sometimes life‑threatening problems:

• Peptic ulcer perforation – Leads to peritonitis and requires emergent surgery.
• Upper gastrointestinal bleeding – May cause anemia requiring transfusion.
• Severe malabsorption – Leads to protein‑calorie deficiency, weight loss, and micronutrient deficiencies (iron, calcium, B12).
• Osteoporosis – Chronic acid suppression and malabsorption increase fracture risk.
• Progression to metastatic disease – Approximately 60–70 % of gastrinomas eventually metastasize, most commonly to the liver and lymph nodes.
• Electrolyte disturbances – Chronic diarrhea can cause hypokalemia, metabolic alkalosis, or dehydration.
• MEN 1‑related tumors – Hyperparathyroidism, pituitary adenomas, and other neuroendocrine tumors may develop, compounding morbidity.

When to Seek Emergency Care

Prompt treatment of these emergencies can be life‑saving.

---

References: Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org; CDC. Neuroendocrine Tumors. https://www.cdc.gov; NIH National Cancer Institute. Gastric Neuroendocrine Tumors. https://www.cancer.gov; Cleveland Clinic. Proton Pump Inhibitor Use. https://my.clevelandclinic.org; WHO. Neuroendocrine Tumors – Classification. https://www.who.int.

```